All In Biotech

NDA 212819 · Msd Merck CO

Recarbrio

Cilastatin Sodium, Imipenem, Relebactam · Intravenous · Penem Antibacterial; Renal Dehydropeptidase Inhibitor; beta Lactamase Inhibitor

NovelPriority reviewDiscontinued

Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jul 16, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

65

21 Phase 3, 2 recruiting

FAERS reports

92

75 serious, 25 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 9, 2025.

RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in adult and pediatric patients weighing at least 2 kg for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) Limitations of Use RECARBRIO is not recommended in pediatric patients less than 37 weeks post-menstrual age (gestational age at birth plus post-natal age). ( 1.4 , 2.2 ). RECARBRIO is not recommended in pediatric patients weighing less than 30 kg with renal impairment. ( 1.4 , 2.3 ). Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) 1.1 Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) RECARBRIO ® is indicated in adult and pediatric patients weighing at least 2 kg for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: Acinetobacter...

Mechanism: RECARBRIO is an antibacterial drug [see Microbiology (12.4) ].

Therapeutic areas: Cardiovascular and metabolic · Infectious disease and vaccines · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 9, 2025 Supplement 8 · Efficacy LetterLabel
  • Jun 4, 2020 Supplement 2 · Efficacy · priority review LabelLetter
  • Jul 16, 2019 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
1 products under this application
  • RECARBRIO · CILASTATIN SODIUM EQ 500MG BASE/VIAL; IMIPENEM 500MG/VIAL; RELEBACTAM 250MG/VIAL · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Cilastatin" as an intervention, any sponsor and status, largest first.

All 65 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use18
  • death14
  • product use in unapproved indication9
  • pathogen resistance8
  • drug ineffective6
  • cardio-respiratory arrest5
  • generalised tonic-clonic seizure5
  • overdose5
  • epilepsy4
  • renal impairment4
  • therapy non-responder4
  • condition aggravated3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20192
202116
202219
202321
202417
202512
20265

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Sep 9, 2026

    RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02). To be discontinued on or near late September 2026.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Recarbrio (Imipenem/Cilastatin/Relebactam)

2024 spending

$1.2M

Beneficiaries

32

178 claims

Per beneficiary

$38,331

$163.65 per unit

View as table
YearSpending
2020$180,002
2021$941,895
2022$1,125,796
2023$1,052,578
2024$1,226,579

Part B: Recarbrio (Imipenem/Cilastatin/Relebactam) · HCPCS J0742

2024 spending

$2K

Beneficiaries

n/a

331 claims

Per beneficiary

n/a

2024 ASP limit $2.48 per unit

View as table
YearSpending
2020$50,507
2021$35,886
2022$0
2023$0
2024$1,916

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 338 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.